Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Search Results

Refine Your Search

By Sector

Sort by: Date|Relevance

Curis' Shares Take Off as FDA Clears IND Application for Monoclonal Anti-VISTA Antibody

Curis Inc. shares are up more than 130% and established a new 52-week high price after reporting that the FDA cleared the company's IND Application for CI-8993, its monoclonal anti-VISTA antibody. Biotechnology company Curis Inc. (CRIS:NASDAQ) , which concentrates...

Reliq Re-establishes Itself as Community Care Technology Leader ...

Reliq Re-establishes Itself as Community Care Technology Leader Amidst Sweeping Federal Medicare/Medicaid Changes A shift in the industry leads to big new contracts and parabolic stock performance for this small cap. A sweeping new development in what federal...

Flying Under the Radar with a Possible COVID-19 Treatment

Investors would think a pharmaceutical company heading into Phase 2b/3 human trials for treating the third most malignant disease after lung cancer and pancreatic cancer would draw eyes from major players. If that same company announced it was embarking on Phase2b/3 human tri...

Allogene Therapeutics Shares Climb 30% on Phase 1 Relapsed/Refractory NHL Study Data

Shares of Allogene Therapeutics traded higher and reached a new 52-week high price after the company reported initial results from its Phase 1 relapsed/refractory non-Hodgkin lymphoma trial. Clinical-stage biotechnology company Allogene Therapeutics Inc. (ALLO:NAS...

Arbutus Biopharma Trades 25% Higher on Phase 1 Hepatitis B Results

Shares of Arbutus Biopharma traded higher after the company reported significant and continuous reduction in HBsAg in 12 chronic hepatitis B subjects using 60 mg dosage of its AB-729 drug. Clinical-stage biopharmaceutical company Arbutus Biopharma Corp. (ABUS:NASD...

The Company that’s taking Psychedelics from ‘Underground to Mainstream’

(Click image to play video) On a trip to Amsterdam, an item on many traveler’s agendas would be to indulge in some famed Dutch truffles. It is an experience to heighten the mind that Canadian public Company Red Light Holland Corp. (TRIP) ( CSE: T...

Marinus Pharma Shares Open Up 41% on Phase 2 Epilepsy Trial Results

Marinus Pharmaceuticals reported positive top-line results for ganaxolone in its Phase 2 refractory status epilepticus trial with all patients achieving the primary endpoint. This morning Marinus Pharmaceuticals Inc. (MRNS:NASDAQ) , a pharmaceutical firm dedicated to...

Moderna Shares Rise 25% on Positive Phase 1 Coronavirus Vaccine Trial Data

Shares of Moderna Inc. traded higher, setting a new 52-week high price, after the firm reported positive interim results in its Phase 1 study of mRNA Vaccine (mRNA-1273) against SARS-CoV-2. Clinical-stage biotechnology company Moderna Inc. (MRNA:NASDAQ) , which fo...

Facing Low Oil Prices, Energy Firm Reduces 2020 Capex, Guidance

The latest moves of Frontera Energy in response to depressed oil prices and its ability to endure the downturn are addressed in a CIBC report. In a March 23 research note, CIBC analyst Dave Popowich reported that Frontera Energy Corp. (FEC:TSX; FECCF:OTCMKT...

Aravive Shares Rise on Positive Patient Data from Phase 1b Ovarian Cancer Study

Shares of Aravive Inc. are trading higher after the firm posted positive data from the initial 12 patients enrolled in the Phase 1b portion of its study of AVB-500 used in the treatment of ovarian cancer. Today, in a late-breaking oral presentation at the European Soc...
1 2 3 4 5 6 7 8 9 10 ...